WuXi Biologics is a global contract development and manufacturing organization (CDMO) focused on biologics. The company provides integrated services spanning discovery, cell line and process development, analytical characterization, technology transfer, clinical and commercial-scale drug substance production, and aseptic drug product (fill-finish) operations. Its expertise covers modalities such as monoclonal antibodies, bispecifics, recombinant proteins, and vaccines.
Headquartered in China and operating a network of GMP-compliant facilities across Asia, Europe, and North America, WuXi Biologics supports biopharmaceutical customers with end-to-end solutions from preclinical studies through commercial supply. The company maintains global quality systems aligned with major regulators and offers CMC, validation, and regulatory filing support to advance the development and manufacturing of biologic therapies.